Understanding how a protein affects gut health and microbiota interactions
Novel roles of Fc gamma binding protein in colonic host-microbiota interactions
This study is looking at a protein called FCGBP in the mucus of the colon to see how it helps keep our gut healthy, especially for people with conditions like ulcerative colitis and colorectal cancer, and it hopes to find new ways to improve treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11166921 on NIH RePORTER |
What this research studies
This research investigates the role of Fc gamma binding protein (FCGBP) in the mucus layer of the colon, which is crucial for gut health. By studying mice with varying levels of FCGBP, the researchers aim to uncover how this protein contributes to the structure of the mucus layer and its interaction with gut bacteria. The study also explores the implications of FCGBP deficiency in conditions like ulcerative colitis and colorectal cancer, potentially revealing new insights into disease mechanisms and treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with ulcerative colitis or colorectal cancer, particularly those with known deficiencies in FCGBP.
Not a fit: Patients without gastrointestinal disorders or those not affected by colorectal diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for colorectal diseases, enhancing patient outcomes.
How similar studies have performed: While the specific role of FCGBP in gut health is not extensively studied, related research on gut microbiota interactions has shown promising results in understanding gastrointestinal diseases.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Maynard, Craig L — University of Alabama at Birmingham
- Study coordinator: Maynard, Craig L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.